Braeburn

Latest news

• New publication shows effectiveness data for weekly and monthly buprenorphine injections in treating opioid dependence in individuals using fentanyl
  26 June 2024
• FDA Approves Brixadi (buprenorphine) Extended-Release Subcutaneous Injection for Moderate to Severe Opioid Use Disorder
  23 May 2023
• FDA Accepts Braeburn's New Drug Application Resubmission for Brixadi (buprenorphine) Extended-Release Subcutaneous Injection for Moderate to Severe Opioid Use Disorder
  8 December 2022
• Braeburn Receives New Complete Response Letter for Brixadi in the US
  15 December 2021
• FDA Accepts Braeburn’s New Drug Application Resubmission for Brixadi (buprenorphine) Extended-Release Subcutaneous Injection for Moderate to Severe Opioid Use Disorder
  26 July 2021
• Braeburn Submits Request for Final Approval of Brixadi (buprenorphine) Extended-Release Injection for the Treatment of Opioid Use Disorder
  1 June 2020
• FDA Grants Braeburn’s Citizen Petition Allowing Brixadi (buprenorphine) Extended-Release Injection for Opioid Use Disorder to be Available in December 2020
  7 November 2019
• Braeburn Announces Tentative FDA Approval of Brixadi (buprenorphine) Extended-Release Injection for the Treatment of Moderate to Severe Opioid Use Disorder
  23 December 2018
• Camurus Announces PDUFA Date for CAM2038 for the Treatment of Opioid Use Disorder
  16 July 2018
• Braeburn Resubmits New Drug Application for CAM2038 for Opioid Use Disorder
  28 May 2018

Drugs Associated with Braeburn Inc.

Braeburn Inc. manufactures, markets and/or distributes 1 drug in the United States. Medications listed here may also be marketed under different names in different countries. Non-US country and region specific information is not available on this page.